anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a stabilized internal drug preparation containing a compound unstable to acid by coating a core part containing a compound unstable to acid with a substance containing suspended fine particles of hardly water-soluble substance and capable of forming a film hardly soluble in water and further coating the coated core with an enteric coating film. CONSTITUTION:A core part (a drug preparation such as tablet, granule or capsule) containing a compound unstable to acid {e.g. benzimidazole compound, especially 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl} methylsulfinyl]-1H- benzimidazole sodium salt} is coated with a substance (B) capable of forming a hardly water-soluble coating film (e.g. ethyl cellulose) containing suspended fine particles of hardly wate-soluble substance (A) such as magnesium oxide or silica. The coated core part is further coated with an enteric coating film (e.g. hydroxypropyl methylcellulose phthalate). The amount of the component A is preferably &gt;=5 wt.% based on the component B.
The present invention provides methods for reducing A.beta. deposition, A.beta. neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer&#39;s disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (-)-nilvadipine, to the animal or human. Further provided are methods for reducing the risk of A.beta.  deposition, A.beta. neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (-)-nilvadipine after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter.
Preparation of a cosmetic treatment formulation for keratinous material, comprises percolation of a fluid at a pressure of &gt;=3 bars through a composition comprising a cosmetic compound in the form of solid or paste in the presence of a anionic hydrotrope i.e. phenyl/pyridine derivative (I). Preparation of a cosmetic treatment formulation for keratinous material, comprises percolation of a fluid at a pressure of &gt;=3 bars through a composition comprising a cosmetic compound in the form of solid or paste in the presence of a anionic hydrotrope i.e. phenyl/pyridine derivative of formula (I). X : -CH= or N; n : 0-12; R1COOM or SO3M; either R2OH or 1-4C alkyl; R3H or 1-4C alkyl; or R2, R35-6 membered, preferably 6 membered ring (optionally substituted by COOM); and M : H or mineral cations i.e. alkaline and/or alkaline earth metal cations, ensuring electroneutrality of (I). Independent claims are included for: (1) a cosmetic treatment of keratinous materials comprising preparing the cosmetic treatment formulation and applying the formulation on keratinous materials; and (2) a packaging device of composition comprising a closed housing bounded by at least a wall at least partially permeable to water vapor under a pressure of &gt;=3 bars, where the composition comprises a cosmetic compound and (I). [Image].
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an ameliorant for blood fluidity that is safe and inexpensive and continuously and readily taken and a food and beverage that ameliorates blood fluidity.  &lt;P&gt;SOLUTION: The ameliorant for blood fluidity comprises catechin as an active ingredient. The food and beverage have amelioration effect on blood fluidity. The ameliorant for blood fluidity and the food and beverage keep blood fluidity in a high state for several hours after intake, namely keeps blood viscosity in a low state. Consequently, crisis risks by rising early morning liable to cause particularly ischemic diseases are reduced by taking the ameliorant for blood fluidity or the food and beverage before going to bed. The ameliorant for blood fluidity and the food and beverage are inexpensive. When the ameliorant for blood fluidity or the beverage is used as a tea-based beverage, it is reasonably taken without largely changing a preceding lifestyle habit.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention relates to a rose mallow active extract, a skin care compound, a preparation method and an application thereof and a skin care product. The main technical scheme adopted is as follows: an active extract of Rosa labra (Thunb.) DC contains ethyl gallate and phenethyl 6&#39; -O-galloyl-beta-D-glucoside. Wherein, in the rose mallow active extract, the mass percentage of the ethyl gallate is not less than 0.325 percent, and the mass percentage of the phenethyl 6&#39; -O-galloyl-beta-D-glucoside is not less than 0.25 percent. A skin care compound is ethyl gallate or phenethyl 6&#39; -O-galloyl-beta-D-glucoside. The invention is mainly used for providing or preparing the rose mallow active extract and separating skin care compounds from the rose mallow active extract; wherein, the rose mallow active extract and the skin care compound can be used as DPPH free radical scavenger and tyrosinase inhibitor, and can be applied to the preparation of anti-aging and whitening skin care products.
PURPOSE:To facilitate the parting of a resin cured body from a plaster mold and to allow the smooth attachment and detachment of this body into and from a patient&#39;s cavity by successively applying water-soluble alginate and an aq. medium soln. of a water-soluble alkaline metal salt over the entire surface of the cavity and adjacent tooth of the plaster mold and drying the coating, then packing and curing a composite resin. CONSTITUTION:The working mold obtd. from the plaster mold is used and the water-soluble alginate is applied over the entire surface of the cavity and the adjacent tooth. The aq. medium soln. of the water-soluble alkaline metal salt is applied on this alginate surface and thereafter, gas is blown to the coated surface to form a smooth surface on the surface of the alginate which is a separating agent. The composite resin for inlay is packed and formed on this surface and is cured; further, the cured body is put into a heat treating device in order to progress the curing.
By converting a component selected from a component derived from a mushroom and  beta -glucan, for example a component derived from a mushroom, particularly an extract of a shiitake mushroom or the like, into superfine particles, preferably by treating an aqueous extract thereof with a dispersant, the incorporation thereof through mucosa can be improved to demonstrate an immune activating action and/or an immune regulating action. The superfine particles (or a composition comprising them) can be used as an immune activator and/or an immune regulator, and thus the invention provides food and drink (health foods, functional foods etc.) and a pharmaceutical composition comprising the superfine particles as an active ingredient, preferably a dispersion obtained by treating the extract thereof with a dispersant. &lt;??&gt;Further, the invention provides a method of activating immunity or a method of regulating immunity and a use of the superfine particles for the immune activator or the immune regulator; or a use of the superfine particles for the antitumor agent, the anti-infective agent, the antiviral agent, the anti-autoimmune disease agent, the anti-diabetes agent, the anti-allergy agent, the pharmaceutical preparation for digestive organ diseases (therapeutic agent for irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), constipation, diarrhea and the like, etc.), or the like. &lt;??&gt;The superfine particles, preferably the dispersion obtained by treating an aqueous mushroom extract etc. with a dispersant, constitute a novel composition, and the invention also provides this novel composition and a process for easily producing the same.
NEW MATERIAL:The tetramethylpiperidine compound of formula and its salt. EXAMPLE:N-[3-(1,5-disulfonaphthyl)]-N&#39;-[4-(2,2,6,6-tetramethyl-1- piperidinoxy)]thiourea sodium salt. USE:Useful as a reagent for electron spin resonance. It can be used over pH1-13 and has high stability at high temperature. Accordingly, the substance permeability through a liposome membrane or cell membrane or the viscosity or polarity in liposome or cell can be estimated by including the compound in liposome. Since the compound is soluble in water and has relatively bulky molecular form, it can be efficiently retained in the aqueous phase in liposome without causing leakage from the liposome. PREPARATION:The compound of formula can be produced by bonding tetramethylpiperidine-N-oxide with naphthalenedisulfonic acid thiourea.
A system allows for collection and re-use of a fluid medium derived from diverting at least some of the fluid medium of an injection. The system comprises a sterile container, an injector, a delivery catheter, a flow diverter assembly and a diversion reservoir assembly. The delivery catheter is in communication with a selected site within a patient&#39;s body. The flow diverter assembly is disposed in a flow path between the injector and the delivery catheter and is configured to divert at least a portion of a medium of the injection from the flow path. The diversion reservoir assembly has a reservoir chamber fluidly coupled to the flow diverter assembly. The reservoir chamber is configured to receive the diverted portion of the fluid medium to allow re-use by the medium injector of the diverted portion.
One or more of the phytocannabinoids tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabichromene (CBC), or cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn&#39;s disease. The one or more phytocannabinoids may be synthetic or isolated. The one or more phytocannabinoids may be present as an extract from a cannabis plant, preferably a botanic drug substance. The botanical drug substance preferably comprises a phytocannabinoid-containing component comprising greater than 50% (w/w) of the botanical drug substance (BDS) and a non-phytocannabinoid containing component comprising less than 50% (w/w) of the BDS. The non-phytocannabinoid containing component may comprise terpenes, sterols, triglycerides, alkanes, squalenes, tocopherols, and carotenoids.
PURPOSE:To provide the titled easily handleable powder having high stability and water dispersibility, by heating a solution containing a sugar composition of maltose and an oligosaccharide at a specific concentration to effect the complete dissolution, cooling the solution, adding and emulsifying lecithin and vitamin A in the solution, and pulverizing the emulsion. CONSTITUTION:A sugar composition of (A) 5-50wt% of maltose or a saccharide composed mainly of maltose and (B) 50-95wt% of an oligosaccharide (e.g. sucrose, lactose, etc.) and/or hydrolyzed starch (e.g. dextrin, starch syrup, etc.) is added with water to adjust the solid sugar concentration of 30-85wt%. The mixture is heated at 90-150 deg.C to effect the complete dissolution of the saccharides, and the resultant sugar solution is cooled to 20-80 deg.C. Lecithin and vitamin A are added to the product, emulsified, and rapidly and efficiently dried to a water-content of &lt;=5%. The obtained dried product containing vitamin A is pulverized to obtain the objective powder. The amount of lecithin is selected to give total phospholipid content of &lt;=20%, especially 1-10% in the powdery vitamin A.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition containing hydrogen peroxide that prevents lowered stability of hydrogen peroxide and gives the hair a favorable touch.  &lt;P&gt;SOLUTION: The composition containing hydrogen peroxide includes (A) hydrogen peroxide, at least (B) one kind selected from guar gum and its derivatives (C) a cationized polymer obtained from a polymer other than cationized guar gum and its derivatives, (D) water, and other components. Preferably the composition contains at least (E) one kind selected from 1- hydroxyethane-1, 1-diphosphonic acid, and its salts. Preferably the composition contains (F) an amphoteric polymer. Preferably component (B) is cationized guar gum. The composition is used for a hair dye, a hair bleach, a dye bleach, etc.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin&#39;s lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
The invention discloses a preparation method and application of a 5-fluorouracil-1-yl bipyridyl acetate copper tetrafluoroborate anticancer functional complex. The invention provides a novel Cu complex [ Cu (bpy) ] 2 L1]BF 4 ·CH 3 Method for synthesizing OH (bpy ═ 2,2&#39; -bipyridine, L1 ═ 5-fluorouracil-1-yl acetic acid) and characterization. The crystal structure of the complex is analyzed by an X-ray diffraction single crystal structure and a differential thermal analysis method, and the complex has certain stability at ambient temperature. Through ultraviolet-visible absorption spectrum method,The fluorescence spectrometry and the electrochemical method study the combination of the complex and the CT-DNA, and the result shows that the complex and the DNA have electrostatic interaction. Furthermore, in vitro cell experiments, the complex [ Cu (bpy) ] 2 L1]BF 4 ·CH 3 OH can better inhibit the growth of human breast cancer cells and human colon cancer cells. Target products prepared based on bio-friendly metal copper show good anti-tumor activity, and the complex [ Cu (bpy) ] 2 L1]BF 4 ·CH 3 OH can be listed as a promising anti-tumor candidate.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a diagnostic method by which the cause of the disease of IgA nephropathy is elucidated or the disease is treated or a burden on patients is reduced.  &lt;P&gt;SOLUTION: A DNA related to IgA nephropathy and a method for obtaining the DNA from leukocytes of a patient suffering from the IgA nephropathy using a differential display method are provided. A method for detecting an mRNA of the IgA nephropathy-related gene comprises using an oligonucleotide based on the base sequence of the DNA. A method for inhibiting the transcription of the IgA nephropathy-related gene and translation of mRNA is provided. A diagnostic agent and a therapeutic agent for the IgA nephropathy comprise the oligonucleotide.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present invention is directed to a method and system for performing an automated sexual function assessment of a female user having a link between the user&#39;s computer and a central computer. After the user registers, obtains a password and a screen name, and provides the user&#39;s demographic information to a database of the central computer, a number of female sexual dysfunction (FSD) questions are displayed on the user&#39;s computer screen in the first phase. Phases two and three questions are then displayed so long as the responses to such FSD questions, that are sent to a user file in the database, indicate a possibility the user has some degree of FSD. The second phase questions relate to psychological causal factors for FSD. The third phase questions relate to medical factors impacting on sexual function. An additional set of questions relating to the quality of the user&#39;s orgasms are usually displayed during the course of the assessment. At the end of the assessment, an evaluation is made of the user&#39;s responses and a determination is made whether the user is a suitable candidate for medical treatment to enhance sexual function if there are no psychological casual or medical factors for FSD and user has no more than a fair satisfaction level on the question of orgasm enjoyment based on an evaluation of the quality of the user&#39;s orgasms.
PURPOSE:To provide a composition for oral cavity application capable of stably maintaining berberine over a long period, by using berberine and a perfumery composition as essential components and restricting the content of a specific aldehyde compound in the perfumery composition. CONSTITUTION:The objective composition for oral cavity application contains 1-3,000ppm of berberine or 0.001-3wt% crude drug extract containing berberine [e.g. extract of OUBAKU (bark of Phellodendron amurense)] and 0.1-10% perfumery composition. In the above composition, the content of 5-12C straight- chain aldehyde compound in the perfumery composition is adjusted to &lt;=0.001%, especially &lt;=0.0001%. The aldehyde perfumery is preferably butanal, isobutylaldehyde, pivalylaldehyde, etc., which does not inhibit the stability of berberine. The characteristic taste and smell of berberine can be masked and the feeling to the palate can be further improved by the addition of the aldehyde perfumery to the composition.
FIELD: genetic engineering, molecular biology. SUBSTANCE: invention relates to vectors comprising defective viral genome that expresses antigen useful for induction of secretory and systemic immune responses and antibody providing protection against infectious agent. The presented defective viral genome is prepared from the parental genome of porcine virus of transmissive gastroenteritis (TGEV) by deleting part of parental genome and retains 3&#39;- and 5&#39;-ends of parental genome with localized recognition signals by viral replicase and at least a promoter. Indicated vectors are useful for design of recombinant system that comprises the indicated expression vector and helper virus. Such system is used for preparing mono- and polyvalent vaccines against infectious agents of animals of different species. Invention proposes also vectors of expression of heterologous genes with high level of safety and capacity of cloning and their construction provides species specificity and tropism that can be controlled easily. EFFECT: valuable properties of vector. 14 cl, 2 tbl, 30 dwg, 5 ex
PURPOSE:To improve both diagnosis and treatment capacity and mutual reliability between a dentist and a paitient by performing an examination and the treatment to the patient at every mouth and using a computers for data on the treatment and business affairs. CONSTITUTION:The diagnosis for the mouth of a received patient is carried out to the patient at every mouth (1). The examination data are written to a mouth examination list and also copied to an examination/treatment record (2). The examination data is fed to a computer and the data analyzed by the computer are printed out (3). The data analyzed by the computer are printed out to a mouth dock examination report and an itemized sheet for the charge estimate of the treatment (4). Counsel is given to a patient which explaining data (5). An original patient&#39;s chart is produced by a computer and the treatment is started. At the same time, a daily examination/treatment record card is produced by a computer and informed to an accounting section together with a dental technician control chart (6). The patient&#39;s chart of complete recovery is printed out (7). The itemized sheet for the examination/treatment fee is produced by a computer (8). In such a way, the integrated treatment processing is attained.
PROBLEM TO BE SOLVED: To obtain a sustained-release treating agent for cerebrovascular dementia containing an oligopeptide having TRH activity. SOLUTION: This agent contains an oligopeptide having TRH activity, e.g. a compound of the formula (X is a 4- to 6-membered heterocycle; Y is imidazol-4-yl, 4-hydroxyphenyl or isopropyl; R&lt;1&gt; and R&lt;2&gt; are each H or a lower alkyl; R&lt;3&gt; is H or a substitutable alkyl; Z is methylene or S) and releases the oligopeptide sustainably. The oligopeptide is preferably formulated into a buried formulation in which the oligopeptide is dispersed in a high molecular matrix, or an injection containing microspheres or microcapsules of the material obtained by crushing the buried formulation or of the oligopeptide itself. The quantity of TRH is 0.001-90% (w/w), preferably 0.01-70% (w/w) as the concentration in an inner water layer. A single dose for an adult is 0.35-35mg (0.007-0.7mg/ kg-body weight) in the case where the sustained-release agent is administered for a week in a basic administration.
Animal pharmaceutical (I) for the temporary inhibition of the reproduction of town pigeons consists of a carrier formed from a hard, non-resorbable matrix in which is homogeneously distributed the active ingredient which is at least one substance which inhibits reproduction. Pref. reproduction inhibitors are sparingly water-soluble and the matrix is a PMMA. Carrier is approximately the size of a grain of maize and coating is coloured and flavoured. Active ingredient is steroid hormones, esp. levonorgestrel and ethynyloestradiol, esp. in amts. of 0.3 mg and 0.1 mg respectively. (I) can also contain other substances which influence reproduction, esp. substances which affect calcium metabolism. USE/ADVANTAGE - (I) is readily eaten by the pigeons, along with their feed and lies in the pigeons&#39; stomachs for several months. Active ingredient is released as (I) is abraded by the stones in the pigeons&#39; stomachs and so a uniform concn. of active ingredient in the birds is obtd. over several months. In female birds, temporary sterilisation is obtd. and in male birds the mating instinct is reduced, while the general health of the birds is unaffected. Pigeon population is reduced by natural deaths and is not over-compensated for by reproduction.